Could The UK Be Losing Its Pharma Luster? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Could The UK Be Losing Its Pharma Luster?
Despite initiatives to encourage multinational pharma companies to conduct R&D in the UK, the country may be losing its edge; is Pfizer's decision to exit a key site earlier this year the beginning of a mass exodus?


Pharmaceutical Technology Europe
Volume 23, Issue 5


Nathan Jessop
When Pfizer decided to close its R&D site in Sandwich it renewed concerns over the UK's attractiveness to the pharma industry. The site employs 2400 people and although Pfizer has stated that some positions will be transferred to other sites or to other companies working with Pfizer, it is expected that most staff will be made redundant over the next two years (1).

Historically, the UK has been one of the leading forces in the world of pharmaceuticals. The pharma industry is also a major contributor to the country's economy. The job losses at Pfizer have come at an unfortunate time with the UK economy still emerging from recession and unemployment remaining high. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the innovative pharmaceutical industry is an "important engine of economic recovery", which means that the UK can ill afford to lose investment from a company of Pfizer's size and stature (2). It's not just Pfizer either; a number of other companies have announced cuts in the UK, including AstraZeneca, GSK and Novartis.

The pharma industry's economic importance to the UK is illustrated by figures from the Association of the British Pharmaceutical Industry (ABPI), which show that the industry has been a net earner for the country for the past 30 years (3). In 2009, the pharmaceutical industry invested 4.4 billion (€5 billion) in UK R&D and employed 72?000 staff. For a number of years, however, EFPIA has been concerned about a drift in investment away from Europe to the US and to the fast-growing economies of Brazil, China and India (2). According to EFPIA, excessive interventions by European national governments to control healthcare expenditure have dented multinational pharma companies' confidence to invest in the region. The organisation will, no doubt, be alarmed by Pfizer's decision to downgrade its investment in the UK, and the fact that it may prompt other large companies to reconsider their presence in the country.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here